CoChat

Cardiovascular disease and risk factors in adults with hypopituitarism

Beshyah, Salem A., Johnston, Desmond G. · 1999 · Clinical Endocrinology
Cited by 121

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Abstract

In 1992, Cuneo et al. (1992) reviewed, in this journal, the consequences of growth (GH) deficiency during adult life and coined the term 'Growth hormone deficiency (GHD) syndrome in adults'. Limited information was available then on cardiovascular disease and risk factors in adults with hypopituitarism. More data have been published since on cardiovascular morbidity in symptom-free hypopituitary adults. Several groups have also published results on the effects of GH therapy on cardiac structure and function and on the cardiovascular risk factors. We shall review here the epidemiological and experimental data on cardiovascular morbidity and mortality in adult hypopituitarism. We shall also examine the prevalence of cardiovascular risk factors in this group of patients and their potential causes focusing on the possible role of GH deficiency and the effects of GH replacement. Life expectancy in hypopituitary patients on routine replacement has been previously assumed to be normal (Hall, 1972). GH deficiency was proposed by others to confer a protective effect against risk of vascular disease from coexisting hyperlipidaemia (De-Gennes et al. 1979). Rosen & Bengtsson (1990) were the first to demonstrate that life expectancy was decreased (Table 1). They examined the records of 333 patients who attended the endocrine clinic in Gothenburg with a diagnosis of hypopituitarism between 1956 and 1987. 104 patients died during the study period and the mortality rate was significantly higher than that in the Swedish population (observed/expected; 1.8, P < 0.001). The excess mortality reflected deaths from vascular disease (Table 1). Myocardial infarction, ischaemic heart disease with congestive cardiac failure and cerebrovascular disease were the most frequent causes of vascular death. Another report from Lund, Sweden (Bulow et al., 1997) on 344 patients diagnosed between 1952 and 1992 demonstrated increased overall mortality (SMR 1.75; 95%CI, 1.4–2.19). It confirmed increased deaths, and in this study, this was particularly due to cerebrovascular disease (SMR 3.39; 95% CI, 1.41–1.88). The increase in cardiovascular mortality was greater in women than in men (SMR. 2.39 vs 1.54). Wüster et al. (1991) examined vascular disease in 122 patients with hypopituitarism in Heidelberg, Germany. The frequency of arteriosclerotic events (myocardial infarctions or strokes) was also higher than that anticipated for the German population. Using the Framingham model, Rosen et al. (1998) calculated the risk of coronary heart disease events from abnormalities of plasma lipids to be 130 events/1000 individuals in GHD men vs 40 events in male controls/1000 individuals and 47 events/1000 individuals in GHD women vs 10 events/1000 individuals in female controls. However, these calculations were though to have very major methodological flaws (Erfurth & Hagmar, 1998). Further attempts at calculating the risk using the frequency of the multiple risk factors observed in hypopituitarism would be welcome. Excess vascular mortality has not been universally observed. Bates et al. (1996) reviewed the case notes of all patients who were investigated for hypopituitarism at North Staffordshire Hospital, UK (Table 1). Of 172 patients who had at least one biochemically demonstrable hormone deficiency, 60 died during the study period. The overall mortality was increased (observed/expected; 1.73, P < 0.01). Vascular disease accounted for 42% of deaths but in this smaller study no significant excess vascular mortality was observed (observed/expected 1.35; P = 0.11). A preliminary report from Birmingham, UK on mortality in a cohort of 349 patients (200 men and 149 women) with pituitary disease diagnosed between 1968 and 1992 has been presented (Bates et al., 1997). The vascular deaths so far has been relatively low (53 men and 29 women died during the study period at a median age of 64 years). The overall observed/expected ratio was increased but there was no excess vascular mortality in either sex. Assessment of adult subjects with GH deficiency since childhood showed no evidence of increased vascular disease (Merimee et al., 1973; Merimee, 1978; Libber et al., 1990). Morbidity and mortality in two other series of patients who had received GH in the UK and Canada were mostly related to recurrence of the underlying pituitary disease or its metabolic complications (Buchanan et al., 1991; Taback et al., 1996). There is therefore evidence for reduced life expectancy in adult-onset hypopituitarism mainly due to vascular disease in some but not all studies. There are not enough data on vascular risk on those who develop GH deficiency during childhood and long-term follow-up studies of these patients into adult life are required. Excess GH secretion in acromegaly is associated with increased heart mass and this decreases following reduction of circulating GH levels (Hirsch et al., 1969; Martins et al., 1977; Mather et al., 1979; Hayward et al., 1987). In experiment

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1046/j.1365-2265.1999.00682.x

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 15 references

Research works printed but not linked: 133

  1. 10.1111/j.1365-2265.1995.tb02602.x · DOI · Paper page
  2. 10.1046/j.1365-2265.1996.d01-1552.x · DOI · Paper page
  3. 10.1210/jc.82.8.2653 · DOI
  4. 10.1210/jc.77.6.1671 · DOI · Paper page
  5. Barmnert M., 1994, Effects of growth hormone replacement therapy on blood pressure regulation and coagulation factors, Endocrinology and Metabolism, 1, 57
  6. Bastenie P.A. Vanhaelst L. Bonnyns M. Neve P.&Staquet E.(1971)Pre‐clinical hypothyroidism: a risk factor for coronary heart disease.Lancet 203–204. · DOI
  7. Bates A.S., 1997, Increased mortality in hypopituitarism is not due to an increase in vascular mortality, Journal of Endocrinology, 152, OC9
  8. 10.1210/jc.81.3.1169 · DOI · Paper page
  9. 10.1210/jc.76.2.309 · DOI · Paper page
  10. Beshyah S.A.(1994) Clinical and metabolic studies on hypopituitarism and growth hormone replacement therapy in adults. PhD Thesis Imperial College University of London London.
  11. 10.1055/s-2007-1002144 · DOI
  12. Beshyah S.A., 1994, Metabolic abnormalities in growth hormone deficient adults. II. Carbohydrate tolerance and lipid metabolism, Endocrinology and Metabolism, 1, 173
  13. 10.1111/j.1365-2265.1995.tb01860.x · DOI · Paper page
  14. 10.1530/eje.0.1300451 · DOI
  15. Beshyah S.A., 1995, Assessment of regional body composition by dual energy X‐ray absorptiometry in hypopituitary adults before and during growth hormone treatment, Endocrinology and Metabolism, 2, 147
  16. 10.1042/cs0890321 · DOI
  17. 10.1111/j.1365-2265.1995.tb02601.x · DOI · Paper page
  18. 10.1210/jc.80.2.356 · DOI · Paper page
  19. Beshyah S.A. Shahi M. Mayet J. Foale R.&Johnston D.G.(1996) Growth hormone and the cardiovascular system. In:The Complexity of Endocrine Systems(eds. M. Ranke & J.S. Christiansen) pp.131–155. J and J‐Verlag Mannaheim.
  20. 10.1136/bmj.1.6007.448 · DOI
  21. 10.1113/jphysiol.1954.sp005085 · doi:10.1113/jphysiol.1954.sp005085
  22. 10.1016/0026-0495(82)90121-4 · DOI
  23. Bojs G., 1965, Haemodynamic studies in man before and after hypophysectomy, Acta Endocrinologica, 39, 308
  24. 10.1210/jcem-61-6-1152 · DOI · Paper page
  25. 10.1016/0002-9343(65)90127-0 · DOI
  26. 10.1136/bmj.302.6780.824 · DOI · Paper page
  27. Burke C.W.(1992) Primary adrenocortical failure. In:Clinical Endocrinology(ed. A. Grossman) pp.393–404. Blackwell Scientific Publications Oxford.
  28. 10.1111/j.1365-2265.1994.tb03937.x · DOI · Paper page
  29. Capaldo B., 1997, Increased arterial intima‐media thickness in childhood‐onset growth hormone deficiency, Journal of Clinical Endocrinology and Metabolism, 82, 1378, 10.1210/jcem.82.5.3951 · doi:10.1210/jcem.82.5.3951 · Paper page
  30. Clarkson P., 1994, Left ventricular diastolic function, Quarterly Journal of Medicine, 87, 143
  31. Cryer P.E.(1992) Glucose homeostatsis and hypoglycaemia. In:William's Textbook of Endocrinology (eds. J.D. Wilson & D.W. Foster) pp.1223–1245. Saunders Philadilphia.
  32. 10.1042/cs0810587 · DOI · Paper page
  33. Cuneo R.C., 1991, Growth hormone treatment in growth hormone deficient adults. II. Effects on exercise performance, Journal of Applied Physiology, 70, 695, 10.1152/jappl.1991.70.2.695 · DOI · Paper page
  34. 10.1016/0026-0495(93)90145-E · DOI · Paper page
  35. 10.1210/jc.83.1.107 · DOI · Paper page
  36. 10.1210/edrv-8-2-115 · DOI · Paper page
  37. De‐Gennes J.L., 1979, Hypopituitarisme et hyperlipidemie. Effet preventif du deficit somatotrope sur le developpement de l'atherosclerose. A propos de 12 observations, Annals Endocrinologie Paris, 40, 557
  38. 10.1210/jc.75.3.833 · DOI · Paper page
  39. 10.1016/0026-0495(94)90245-3 · DOI · Paper page
  40. 10.1046/j.1365-2265.1997.2101025.x · DOI · Paper page
  41. Drury P.L.&Besser G.M.(1989) Adrenal cortex. In:Fundamentals of Clinical Endocrinology(eds. R. Hall & G.M. Besser) pp.153–184. Churchill Livingstone London.
  42. 10.1161/01.ATV.13.2.296 · DOI · Paper page
  43. 10.1046/j.1365-2265.1998.00589.x · DOI
  44. 10.1111/j.1365-2265.1981.tb00634.x · DOI · Paper page
  45. 10.1046/j.1365-2265.1996.830895.x · DOI · Paper page
  46. Fort S., 1995, The effect of low‐dose recombinant human growth hormone on cardiovascular structure and function in growth hormone‐deficient hypopituitary adults, Endocrinology and Metabolism, 2, 119
  47. 10.1111/j.1365-2265.1995.tb00541.x · DOI
  48. 10.1016/0026-0495(93)90197-V · DOI · Paper page
  49. 10.1136/bmj.303.6804.704 · DOI
  50. 10.1046/j.1365-2265.1998.00364.x · doi:10.1046/j.1365-2265.1998.00364.x · Paper page
  51. 10.1111/j.1365-2796.1994.tb01099.x · DOI
  52. 10.1016/0026-0495(91)90037-W · DOI · Paper page
  53. 10.2337/diacare.9.2.153 · DOI · Paper page
  54. Hall R., 1972, Diagnosis and management of hypopituitarism, Journal of the Royal College of Physicians of London, 7, 19
  55. Hayward R.P., 1987, Acromegalic heart disease; influence of the treatment of the acromegaly on the heart, Quarterly Journal of Medicine, 62, 41
  56. Hew F.L., 1995, Insulin Tolerance sensitivity in patients with anterior pituitary hormone deficiency: reduced insulin sensitivity, Endocrinology and Metabolism, 2, 93
  57. 10.1097/00000441-196901000-00001 · doi:10.1097/00000441-196901000-00001
  58. Hjalmarson A., 1969, Effects of growth hormone and insulin on amino acid transport in perfused rat heart, American Journal of Physiology, 217, 1795, 10.1152/ajplegacy.1969.217.6.1795 · doi:10.1152/ajplegacy.1969.217.6.1795
  59. 10.1016/0026-0495(90)90065-K · DOI
  60. Hopwood N.J., 1975, Hypoglycaemia in hypopituitary children, American Journal of Diseases of Children, 129, 918
  61. 10.1016/S0300-595X(85)80083-9 · DOI · Paper page
  62. 10.1210/jc.82.10.3285 · DOI
  63. Ishibashi S., 1985, Hyperlipidaemia in patients with hypopituitarism, Acta Endocrinologica, 110, 456
  64. 10.1046/j.1365-2265.1996.00820.x · DOI · Paper page
  65. 10.1210/jc.82.3.727 · DOI · Paper page
  66. 10.1161/01.ATV.14.3.434 · DOI · Paper page
  67. Johansson J.‐O., 1996, Long‐term treatment with growth hormone decreases plasminogen activator inhibitor‐1 and tissue plasminogen activator in growth hormone‐deficient adults, Thrombosis and Haemostasis, 76, 422, 10.1055/s-0038-1650594 · DOI · Paper page
  68. 10.1016/0026-0495(80)90215-2 · DOI
  69. 10.3109/00365519009091600 · DOI
  70. 10.1016/S0140-6736(89)92328-3 · DOI · Paper page
  71. 10.1111/j.1365-2265.1976.tb03801.x · doi:10.1111/j.1365-2265.1976.tb03801.x · Paper page
  72. 10.1210/jcem-54-2-254 · DOI · Paper page
  73. 10.1016/0021-9150(93)90189-2 · DOI
  74. 10.1046/j.1365-2265.1997.d01-1743.x · doi:10.1046/j.1365-2265.1997.d01-1743.x
  75. 10.1136/bmj.289.6454.1257 · DOI · Paper page
  76. 10.1136/bmj.288.6428.1401 · DOI · Paper page
  77. 10.1016/0140-6736(92)93210-E · DOI
  78. 10.1111/j.1464-5491.1992.tb01746.x · DOI · Paper page
  79. 10.1016/0140-6736(93)92664-F · DOI
  80. Lehmann E.D., 1994, Blood pressure corrected aortic distensibility in growth hormone deficient adults, Clinical Science, 83, 64
  81. 10.1093/ajcn/55.5.950 · DOI · Paper page
  82. 10.1097/00005792-199001000-00004 · DOI · Paper page
  83. 10.1111/j.1365-2796.1995.tb01216.x · DOI
  84. 10.1046/j.1365-2265.1998.00281.x · DOI · Paper page
  85. 10.1530/eje.0.1360157 · DOI · Paper page
  86. 10.1161/01.CIR.56.5.863 · DOI
  87. 10.1136/hrt.41.6.697 · DOI
  88. 10.3109/10641969409068584 · DOI
  89. 10.1161/01.CIR.70.4.547 · DOI · Paper page
  90. 10.1172/JCI106527 · DOI · Paper page
  91. 10.1016/0026-0495(72)90036-4 · DOI
  92. 10.2337/diab.22.11.813 · DOI
  93. 10.1056/NEJM197806012982202 · DOI
  94. 10.1210/jc.77.6.1658 · doi:10.1210/jc.77.6.1658 · Paper page
  95. Modgiliani E., 1994, Modification of blood lipids and lipoproteins after human growth hormone treatment in adults with growth hormone deficiency: a preliminary report, Endocrinology and Metabolism, 1, 31
  96. 10.1046/j.1365-2265.1997.87897.x · DOI
  97. 10.1210/jc.80.2.552 · DOI · Paper page
  98. 10.1530/eje.0.1370459 · DOI
  99. 10.1177/000456329603300408 · DOI
  100. 10.1210/jc.79.4.975 · DOI · Paper page
  101. 10.1136/bmj.306.6894.1726-a · DOI
  102. 10.1161/01.ATV.15.7.847 · DOI
  103. Padayatty S.J., 1993, The effects ofsulin‐like growth factor‐1 on plasminogen activator inhibitor‐1 synthesis and secretion: results from in vitro and in vivo studies, Thrombosis and Haemostasis, 70, 1009, 10.1055/s-0038-1649716 · DOI
  104. 10.1111/j.1464-5491.1994.tb00369.x · DOI
  105. 10.1016/0002-9343(52)90027-2 · DOI · Paper page
  106. 10.1002/dmr.5610040406 · DOI
  107. 10.2337/diab.15.1.24 · DOI
  108. 10.1111/j.1365-2265.1996.tb02057.x · DOI · Paper page
  109. 10.1530/acta.0.1290195 · DOI · Paper page
  110. 10.1111/j.1365-2265.1993.tb00974.x · DOI · Paper page
  111. Rosen T., 1994, Beneficial effects of 12 months replacement therapy with recombinant human growth hormone to growth hormone deficient adults, Endocrinology and Metabolism, 1, 55
  112. 10.1046/j.1365-2265.1998.00473.x · DOI
  113. 10.1111/j.1365-2265.1994.tb02555.x · DOI · Paper page
  114. 10.1210/jcem-49-5-753 · doi:10.1210/jcem-49-5-753
  115. 10.1042/cs0870201 · DOI · Paper page
  116. Salonen J.T., 1993, Ultrasound B‐mode imaging in observational studies of atherosclerotic progression, Circulation, 87, II56
  117. 10.1111/j.1365-2265.1978.tb01516.x · DOI · Paper page
  118. 10.1136/hrt.67.1.92 · DOI · Paper page
  119. 10.1093/ajcn/61.6.1290 · DOI
  120. Stiegler C., 1994, One year of replacement therapy in adults with growth hormone deficiency, Endocrinology and Metabolism, 1, 37
  121. 10.1210/jc.81.5.1693 · DOI · Paper page
  122. 10.1111/j.1365-2265.1991.tb00287.x · DOI
  123. 10.1111/j.1365-2265.1994.tb01827.x · DOI · Paper page
  124. 10.1046/j.1365-2265.1996.8310842.x · DOI
  125. 10.1093/ajcn/4.1.20 · DOI · Paper page
  126. 10.1210/jc.80.2.659 · DOI · Paper page
  127. 10.1046/j.1365-2265.1998.00575.x · DOI · Paper page
  128. 10.1111/j.1365-2265.1994.tb01830.x · DOI · Paper page
  129. 10.1210/jc.80.1.153 · DOI · Paper page
  130. 10.3181/00379727-173-41610 · doi:10.3181/00379727-173-41610
  131. 10.1111/j.1365-2265.1992.tb02901.x · DOI · Paper page
  132. 10.1016/0026-0495(79)90138-0 · DOI
  133. 10.1007/BF01797616 · DOI

Cited by

See all 121

Metadata

Authors
Beshyah, S. A., & Johnston, D. G.
Venue
Clinical Endocrinology
Publisher
Wiley
Published
1999-01
Volume
50
Issue
1
Pages
1-15
ISSN
  • 0300-0664 (ISSN-L)
  • 1365-2265
OpenAlex
W2049712554
Cited by
121
References
15
FWCI
5.32
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cardiovascular disease and risk factors in adults with hypopituitarism. https://app.cochat.ai/papers/10.1046/j.1365-2265.1999.00682.x
The paper
Beshyah, S. A., & Johnston, D. G. (1999). Cardiovascular disease and risk factors in adults with hypopituitarism. Clinical Endocrinology. https://doi.org/10.1046/j.1365-2265.1999.00682.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.